Understand Where T-Cell Engager Innovation is Really Heading
T-cell engager (TCE) innovation is accelerating rapidly, with patent filings more than doubling since 2018 as development shifts toward next‑generation formats such as trispecifics and ADC‑based TCEs. Despite this expansion, activity remains heavily concentrated in oncology, which still accounts for 83% of patent filings, while emerging modalities are driving the fastest growth. The commercial potential of this space is underscored by landmark deals, including the $22.2B Daiichi Sankyo and Merck collaboration, alongside a growing pool of 168 disclosed trispecific assets, an increasing proportion of which are progressing into clinical development. Together, these trends highlight a landscape where innovation is scaling quickly in complexity, but only a select subset is translating into pipelines.
Download the infographic to explore the full T‑cell engager landscape and uncover:
- How patent activity is evolving across regions and modalities
- Which next‑generation formats are gaining the most momentum
- Where innovation is translating into clinical pipelines, and where it is not
- How dealmaking, patenting, and pipeline progression are diverging
- What these trends mean for competitive positioning and R&D strategy
Access the infographic now to get a clear, data‑driven view of where the TCE market is heading and where the biggest opportunities lie.
You May Also Be Interested In…
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
